TG Therapeutics (NASDAQ: TGTX) reported Q1 EPS of ($0.07), $0.03 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $63.5 million versus the consensus estimate of $54.58 million.

2024 Updated Target U.S. BRIUMVI Guidance

• Q2 2024 target BRIUMVI U.S. net product revenue of approximately $65 million
• Updating BRIUMVI U.S. net product revenue target to approximately $270 million to $290 million for the full year 2024 (prior guidance of $220 to $260 million for full year 2024)

2024 Development Pipeline Anticipated Milestones

• Commence clinical development of subcutaneous BRIUMVI
• Commence a clinical trial evaluating BRIUMVI in an additional autoimmune disease outside of multiple sclerosis (MS)
• Commence a clinical trial evaluating azer-cel in autoimmune disease
• Present data from the ENHANCE Phase 3b CD20 switch trial at multiple conferences throughout the year

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.